Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;56(7):1761-1763.
doi: 10.1038/s41409-021-01280-3. Epub 2021 Apr 12.

Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population

Lauren C Shapiro  1 , Jennat Mustafa  1 , Amanda Lombardo  1 , Fariha Khatun  1 , Felisha Joseph  1 , Kailyn Gillick  1 , Anjali Naik  1 , Richard Elkind  1 , Michelly Abreu  1 , Karen Fehn  1 , Alyssa de Castro  2 , Kith Pradhan  1 , Donika Binakaj  1 , Randin Nelson  3 , Monika Paroder  3 , Joan Uehlinger  3 , Kira Gritsman  1 , R Alejandro Sica  1 , Noah Kornblum  1 , Aditi Shastri  1 , Ioannis Mantzaris  1 , Lizamarie Bachier-Rodriguez  1 , Amit Verma  1 , Ira Braunschweig  1 , Mendel Goldfinger  4
Affiliations

Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population

Lauren C Shapiro et al. Bone Marrow Transplant. 2021 Jul.
No abstract available

PubMed Disclaimer

References

    1. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A Predictive Model For Aggressive Non-Hodgkin’s Lymphoma. N Engl J Med. 1993;329:987–94. - DOI
    1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma. N Engl J Med. 2017;377:2531–44. - DOI
    1. Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135:2106–9. - DOI
    1. Sharma P, Singh H, Bouchkouj N, Krauss AC, George B. A U.S Food and Drug Administration Age Based Pooled Analysis of Cytokine Release Syndrome and Neurotoxicity in Subjects with Relapsed/Refractory Lymphoma Treated with Chimeric Antigen Receptor (CAR) T Cell Therapy [abstract]. Blood. 2018;132:Abstract 4201. - DOI
    1. Sano D, Lekakis L, Feng L, Nastoupil LJ, Jain MD, Spiegel JY, et al. Safety and Efficacy of Axicabtagene Ciloleucel (Axi-Cel) in Older Patients: Results from the US Lymphoma CAR-T Consortium. Hematol Oncol. 2019;37:304–5. - DOI

LinkOut - more resources